Qiong Wang, Shenghan Gao, Wensheng Zhang, Yunxia Zhao, Yi He, W. Sun, Feng-Na Zhang, Tong Yu, Lihong Zhou, Zheng-Rong Ye, Jian-ming Su, Shunnan Zhang, Yongfa Chen
Mental health disorders such as stress, anxiety, depression and insomnia caused by COVID-19 have attracted worldwide attention. Traditional Chinese medicines (TCMs) have been proven to be a safe and effective option for treating mental health disorders. Recently, after assessing its efficacy and safety fully, the Netherlands Medicines Evaluation Board approved XiaoYao Tablets as a traditional herbal medicinal product (THMP), indicated for an alternative self-care for patients in Europe to relieve the symptoms of mental stress and exhaustion. Despite the fact that TCMs have gradually become one of the therapeutic choices worldwide, to-date, only a few TCMs have been successfully registered in the European Union (EU) as THMPs, and XiaoYao Tablets is the first successfully registered combination TCM from China. In this article, traditional use efficacy and clinical safety of XiaoYao Tablets in the treatment of mental health disorders were summarized and analyzed from the perspective of traditional use registration (TUR). Additionally a safety evolution pathway of combination TCMs was established. This article will not only seek to enhance our understanding about traditional use efficacy and clinical safety of XiaoYao Tablets, but also summarize the experience of XiaoYao Tablets as the first successfully registered combination TCM from China, which could serve as role model for the others to overcome registration difficulties in the EU.
{"title":"Traditional use and safety evaluation of combination Traditional Chinese Medicine in European registration: with XiaoYao Tablets as an example.","authors":"Qiong Wang, Shenghan Gao, Wensheng Zhang, Yunxia Zhao, Yi He, W. Sun, Feng-Na Zhang, Tong Yu, Lihong Zhou, Zheng-Rong Ye, Jian-ming Su, Shunnan Zhang, Yongfa Chen","doi":"10.1691/ph.2022.1227","DOIUrl":"https://doi.org/10.1691/ph.2022.1227","url":null,"abstract":"Mental health disorders such as stress, anxiety, depression and insomnia caused by COVID-19 have attracted worldwide attention. Traditional Chinese medicines (TCMs) have been proven to be a safe and effective option for treating mental health disorders. Recently, after assessing its efficacy and safety fully, the Netherlands Medicines Evaluation Board approved XiaoYao Tablets as a traditional herbal medicinal product (THMP), indicated for an alternative self-care for patients in Europe to relieve the symptoms of mental stress and exhaustion. Despite the fact that TCMs have gradually become one of the therapeutic choices worldwide, to-date, only a few TCMs have been successfully registered in the European Union (EU) as THMPs, and XiaoYao Tablets is the first successfully registered combination TCM from China. In this article, traditional use efficacy and clinical safety of XiaoYao Tablets in the treatment of mental health disorders were summarized and analyzed from the perspective of traditional use registration (TUR). Additionally a safety evolution pathway of combination TCMs was established. This article will not only seek to enhance our understanding about traditional use efficacy and clinical safety of XiaoYao Tablets, but also summarize the experience of XiaoYao Tablets as the first successfully registered combination TCM from China, which could serve as role model for the others to overcome registration difficulties in the EU.","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"1 1","pages":"125-130"},"PeriodicalIF":0.0,"publicationDate":"2022-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82374294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hui Zhou, Binghua Yao, L. Qian, Haozhong Hu, Qingning Duan
Radiotherapy is a common treatment for lung cancer. However, radiation pneumonitis caused by radiotherapy can affect the quality of life and prognosis of lung cancer patients. miR-513a-3p has been found to sensitize human lung adenocarcinoma cells to chemotherapy by targeting glutathione S-transferase P1 (GSTP1). Here, we found that x-ray induced the apoptosis of BEAS-2B and miR-513a-3p expression in a dose- and time-dependent manner, and miR-513a-3p-mimic significantly increased x-ray induced apoptosis, while miR-513a-3p-inhibitor significantly decreased x-ray induced apoptosis. Dual luciferase gene reporter system showed that miR-513a-3p targeted to inhibit the expression of GSTP1 in BEAS-2B cells. Moreover, knockdown of GSTP1 significantly increased, while overexpression of GSTP1 decreased the apoptosis of BEAS-2B induced by x-ray. Importantly, overexpression of GSTP1 significantly reduced miR-513a-3p-mimic elevated x-ray -induced apoptosis in BEAS-2B cells. In conclusion, x-ray caused increased expression of miR-513a-3p, and miR-513a-3p promoted x-ray-induced apoptosis of human lung cells by inhibiting GSTP1.
{"title":"MiR-513a-3p promotes radiation-induced apoptosis of human lung cells by inhibiting glutathione S-transferase P1.","authors":"Hui Zhou, Binghua Yao, L. Qian, Haozhong Hu, Qingning Duan","doi":"10.1691/ph.2022.1872","DOIUrl":"https://doi.org/10.1691/ph.2022.1872","url":null,"abstract":"Radiotherapy is a common treatment for lung cancer. However, radiation pneumonitis caused by radiotherapy can affect the quality of life and prognosis of lung cancer patients. miR-513a-3p has been found to sensitize human lung adenocarcinoma cells to chemotherapy by targeting glutathione S-transferase P1 (GSTP1). Here, we found that x-ray induced the apoptosis of BEAS-2B and miR-513a-3p expression in a dose- and time-dependent manner, and miR-513a-3p-mimic significantly increased x-ray induced apoptosis, while miR-513a-3p-inhibitor significantly decreased x-ray induced apoptosis. Dual luciferase gene reporter system showed that miR-513a-3p targeted to inhibit the expression of GSTP1 in BEAS-2B cells. Moreover, knockdown of GSTP1 significantly increased, while overexpression of GSTP1 decreased the apoptosis of BEAS-2B induced by x-ray. Importantly, overexpression of GSTP1 significantly reduced miR-513a-3p-mimic elevated x-ray -induced apoptosis in BEAS-2B cells. In conclusion, x-ray caused increased expression of miR-513a-3p, and miR-513a-3p promoted x-ray-induced apoptosis of human lung cells by inhibiting GSTP1.","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"6 11","pages":"121-124"},"PeriodicalIF":0.0,"publicationDate":"2022-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91402307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Hossain, S. C. Hall, P. J. Wiggington, S. Roth, S. Das, U. Das, P. K. Roayapalley, J. Dimmock
The present investigation involved the synthesis of a number of novel benzylidene hydrazides as candidate cytotoxic agents. The preparation of these compounds from terephthalic acid and isophthalic acid proceeded satisfactorily. However, the reaction of phthalic acid hydrazide with various aryl aldehydes was unsuccessful in general. Some of the unexpected products were identified. The shapes and also the distances between the centers of the aryl rings designated B and C of three representative compounds 1b, 2b and 3b were determined. The compounds designated 1a-e, 2a-e and 3b were screened against human HCT116 and HT29 colon cancer cells as well as human CRL1790 non-malignant colon cells which revealed the tumor-selective toxicity displayed by these compounds.
{"title":"Cytotoxic benzylidene hydrazides of terephthalic acid and related compounds.","authors":"M. Hossain, S. C. Hall, P. J. Wiggington, S. Roth, S. Das, U. Das, P. K. Roayapalley, J. Dimmock","doi":"10.1691/ph.2022.11072","DOIUrl":"https://doi.org/10.1691/ph.2022.11072","url":null,"abstract":"The present investigation involved the synthesis of a number of novel benzylidene hydrazides as candidate cytotoxic agents. The preparation of these compounds from terephthalic acid and isophthalic acid proceeded satisfactorily. However, the reaction of phthalic acid hydrazide with various aryl aldehydes was unsuccessful in general. Some of the unexpected products were identified. The shapes and also the distances between the centers of the aryl rings designated B and C of three representative compounds 1b, 2b and 3b were determined. The compounds designated 1a-e, 2a-e and 3b were screened against human HCT116 and HT29 colon cancer cells as well as human CRL1790 non-malignant colon cells which revealed the tumor-selective toxicity displayed by these compounds.","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"10 1","pages":"90-94"},"PeriodicalIF":0.0,"publicationDate":"2022-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79135010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Huanbutta, K. Thanawuth, L. Sutthapitaksakul, S. Piriyaprasarth, K. Cheewatanakornkool, S. Maksup, K. Theeratanapartkul, P. Sathorn, P. Phusamlee, T. Kwanjaiphanich, T. Sangnim, P. Sriamornsak
This study aimed to develop and optimize a topical Clinacanthus nutans liquid spray that dries quickly after spraying and has low stickiness. An experimental design was adopted to evaluate the effects of the amounts of polyvinylpyrrolidone (X1) and glycerol (X₂) and the ratio of acetone:ethanol (X₃) on the stickiness (Y1 ), solution viscosity (Y₂), evaporation rate (Y₃), and spray coverage radius (Y₄) of the solution. Results revealed that all independent factors had a substantial effect on Y1 -Y₃. In this model, the synergistic effect was uncommon. The optimized formulation consisted of X1 of 0.1%, X₂ of 1.0%, and X₃ of 59:41. The response values of Y1, Y₂, Y₃, and Y₄ were 92.24 mN, 4.63 cP, 0.0959%, and 9.40 cm, respectively. The actual results were close to those predicted by the experimental design model. Therefore, the optimized topical spray formulation can be used in actual practice.
{"title":"Development and optimization of Clinacanthus nutans liquid spray using a two-level full factorial design.","authors":"K. Huanbutta, K. Thanawuth, L. Sutthapitaksakul, S. Piriyaprasarth, K. Cheewatanakornkool, S. Maksup, K. Theeratanapartkul, P. Sathorn, P. Phusamlee, T. Kwanjaiphanich, T. Sangnim, P. Sriamornsak","doi":"10.1691/ph.2022.1236","DOIUrl":"https://doi.org/10.1691/ph.2022.1236","url":null,"abstract":"This study aimed to develop and optimize a topical Clinacanthus nutans liquid spray that dries quickly after spraying and has low stickiness. An experimental design was adopted to evaluate the effects of the amounts of polyvinylpyrrolidone (X1) and glycerol (X₂) and the ratio of acetone:ethanol (X₃) on the stickiness (Y1 ), solution viscosity (Y₂), evaporation rate (Y₃), and spray coverage radius (Y₄) of the solution. Results revealed that all independent factors had a substantial effect on Y1 -Y₃. In this model, the synergistic effect was uncommon. The optimized formulation consisted of X1 of 0.1%, X₂ of 1.0%, and X₃ of 59:41. The response values of Y1, Y₂, Y₃, and Y₄ were 92.24 mN, 4.63 cP, 0.0959%, and 9.40 cm, respectively. The actual results were close to those predicted by the experimental design model. Therefore, the optimized topical spray formulation can be used in actual practice.","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"12 1","pages":"107-111"},"PeriodicalIF":0.0,"publicationDate":"2022-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81449680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yiwei Hu, Huiting Qu, Jie He, Hongyao Zhong, Shoukai He, P. Zhao, Leyao Zhang, Jinghua Chen, Chao Deng
Exosomes are a type of nanoparticles in 40-200 nm extracellular vesicles secreted from living cells, containing a plurality of biologically active substances, which can be used as carriers of intercellular delivery signals. Among them, mesenchymal stem cell (MSC)-derived exosomes have been reported to play important roles in injury repair, alleviating inflammation; thus, MSC-derived exosomes have become hot spot in noncellular therapies. The role of human placental MSC-derived exosomes (hplMSC-Exos) in inflammation and their potential mechanisms are unclear. Therefore, we investigated the anti-inflammatory effects of hplMSC-Exos in lipopolysaccharide (LPS)-induced RAW264.7 cells and their intrinsic mechanisms. Our data demonstrated that hplMSCs-Exos can adjust inflammation by regulating TLR4-mediated NF-κB/MAPK and PI3K signaling pathways, indicating that hplMSCs-Exos can act as a new strategy for inflammatory treatment.
{"title":"Human placental mesenchymal stem cell derived exosomes exhibit anti-inflammatory effects via TLR4-mediated NF-κB/MAPK and PI3K signaling pathways.","authors":"Yiwei Hu, Huiting Qu, Jie He, Hongyao Zhong, Shoukai He, P. Zhao, Leyao Zhang, Jinghua Chen, Chao Deng","doi":"10.1691/ph.2022.11082","DOIUrl":"https://doi.org/10.1691/ph.2022.11082","url":null,"abstract":"Exosomes are a type of nanoparticles in 40-200 nm extracellular vesicles secreted from living cells, containing a plurality of biologically active substances, which can be used as carriers of intercellular delivery signals. Among them, mesenchymal stem cell (MSC)-derived exosomes have been reported to play important roles in injury repair, alleviating inflammation; thus, MSC-derived exosomes have become hot spot in noncellular therapies. The role of human placental MSC-derived exosomes (hplMSC-Exos) in inflammation and their potential mechanisms are unclear. Therefore, we investigated the anti-inflammatory effects of hplMSC-Exos in lipopolysaccharide (LPS)-induced RAW264.7 cells and their intrinsic mechanisms. Our data demonstrated that hplMSCs-Exos can adjust inflammation by regulating TLR4-mediated NF-κB/MAPK and PI3K signaling pathways, indicating that hplMSCs-Exos can act as a new strategy for inflammatory treatment.","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"11 1","pages":"112-117"},"PeriodicalIF":0.0,"publicationDate":"2022-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88691253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Nagai, S. Fukuno, R. Moriwaki, H. Kuroda, S. Omotani, T. Miura, Y. Hatsuda, M. Myotoku, H. Konishi
In the present study, we examined the effects of concurrent and staggered dosing of PG-soft ace-MP TM (PG), novel semi-solid enteral nutrients, on the pharmacokinetics of orally administered carbamazepine (CBZ) in rats due to the high possibility of drug interaction during the absorption process. The pharmacokinetic behavior of CBZ was considerably altered when administered concurrently with PG. The maximum serum CBZ concentration (Cmax) significantly decreased and the mean residence time (MRT) significantly increased. The elimination constant (ke) also significantly increased, but there were no significant changes in the area under the serum CBZ concentration versus time curve (AUC) and the time to reach Cmax (Tmax). However, these changes in the pharmacokinetic parameters were eliminated by waiting 20 min, the time interval equivalent to the Tmax described above, between CBZ administration and PG dosing. This study suggested that PG interferes with CBZ absorption from the digestive tract, although staggered administration of CBZ and PG prevented their interaction.
{"title":"Influence of concurrent and staggered dosing of semi-solid nutrients on the pharmacokinetics of orally administered carbamazepine in rats.","authors":"K. Nagai, S. Fukuno, R. Moriwaki, H. Kuroda, S. Omotani, T. Miura, Y. Hatsuda, M. Myotoku, H. Konishi","doi":"10.1691/2022.1756","DOIUrl":"https://doi.org/10.1691/2022.1756","url":null,"abstract":"In the present study, we examined the effects of concurrent and staggered dosing of PG-soft ace-MP TM (PG), novel semi-solid enteral nutrients, on the pharmacokinetics of orally administered carbamazepine (CBZ) in rats due to the high possibility of drug interaction during the absorption process. The pharmacokinetic behavior of CBZ was considerably altered when administered concurrently with PG. The maximum serum CBZ concentration (Cmax) significantly decreased and the mean residence time (MRT) significantly increased. The elimination constant (ke) also significantly increased, but there were no significant changes in the area under the serum CBZ concentration versus time curve (AUC) and the time to reach Cmax (Tmax). However, these changes in the pharmacokinetic parameters were eliminated by waiting 20 min, the time interval equivalent to the Tmax described above, between CBZ administration and PG dosing. This study suggested that PG interferes with CBZ absorption from the digestive tract, although staggered administration of CBZ and PG prevented their interaction.","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"21 1","pages":"118-120"},"PeriodicalIF":0.0,"publicationDate":"2022-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85724098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-13DOI: 10.21203/rs.3.rs-858889/v1
T. Ichimura, C. Ogawa, Hayato Murata, K. Miyahara, Satoshi Yuge, R. Tsukioka, Keisuke Kado, Tomonobu Yoshimura, Kenichi Suzuki, H. Nomura, Hisanori Shimizu
Patients experiencing severe side effects when taking high-risk drugs may have a significantly reduced health-related quality of life (QOL); therefore, it is important to identify changes in the health-related QOL in these patients. This study aimed to determine the health-related QOL in community pharmacy outpatients taking high-risk drugs. This prospective observational study was conducted in 29 community pharmacies with 71 pharmacists in 12 regions and cities in Japan from October to December 2020 and 760 patients were enrolled. Using descriptive questionnaires of EuroQOL-5-dimensions-5-levels (EQ-5D-5L), community pharmacists obtained health-related QOL data from outpatients taking high-risk drugs. The mean health-related QOL of all outpatients was 0.869. The health-related QOL decreased with increasing age. The outpatient health-related QOL was 0.700, 0.763, 0.785, and 0.817 when taking antiepileptic, antidepressant, digitalis, and antiarrhythmic drugs, respectively, which was lower than the average health-related QOL of all outpatients. Mobility and pain/ discomfort accounted for a large proportion of the decline in the health-related QOL with increasing age. There were no significant differences in personal care with increasing age; however, the number of outpatients with mobility, normal activity, and pain challenges decreased with age. In contrast, outpatients aged <65 years with anxiety/depression showed a lower than overall average health-related QOL. To the best of our knowledge, this is the first study in Japan to report an investigation by community pharmacists regarding health-related QOL assessment in outpatients taking high-risk drugs.
{"title":"Community pharmacists' measurement of health-related quality of life in outpatients taking high-risk drugs.","authors":"T. Ichimura, C. Ogawa, Hayato Murata, K. Miyahara, Satoshi Yuge, R. Tsukioka, Keisuke Kado, Tomonobu Yoshimura, Kenichi Suzuki, H. Nomura, Hisanori Shimizu","doi":"10.21203/rs.3.rs-858889/v1","DOIUrl":"https://doi.org/10.21203/rs.3.rs-858889/v1","url":null,"abstract":"Patients experiencing severe side effects when taking high-risk drugs may have a significantly reduced health-related quality of life (QOL); therefore, it is important to identify changes in the health-related QOL in these patients. This study aimed to determine the health-related QOL in community pharmacy outpatients taking high-risk drugs. This prospective observational study was conducted in 29 community pharmacies with 71 pharmacists in 12 regions and cities in Japan from October to December 2020 and 760 patients were enrolled. Using descriptive questionnaires of EuroQOL-5-dimensions-5-levels (EQ-5D-5L), community pharmacists obtained health-related QOL data from outpatients taking high-risk drugs. The mean health-related QOL of all outpatients was 0.869. The health-related QOL decreased with increasing age. The outpatient health-related QOL was 0.700, 0.763, 0.785, and 0.817 when taking antiepileptic, antidepressant, digitalis, and antiarrhythmic drugs, respectively, which was lower than the average health-related QOL of all outpatients. Mobility and pain/ discomfort accounted for a large proportion of the decline in the health-related QOL with increasing age. There were no significant differences in personal care with increasing age; however, the number of outpatients with mobility, normal activity, and pain challenges decreased with age. In contrast, outpatients aged <65 years with anxiety/depression showed a lower than overall average health-related QOL. To the best of our knowledge, this is the first study in Japan to report an investigation by community pharmacists regarding health-related QOL assessment in outpatients taking high-risk drugs.","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"12 1","pages":"202-206"},"PeriodicalIF":0.0,"publicationDate":"2021-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91048136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
I. Samardžić, I. Marinović, I. Matković, I. Mamic, V. Vrca
{"title":"Antimicrobial drugs involved in potential drug-drug-interactions in cardiosurgical patients","authors":"I. Samardžić, I. Marinović, I. Matković, I. Mamic, V. Vrca","doi":"10.1691/PH.2021.0774","DOIUrl":"https://doi.org/10.1691/PH.2021.0774","url":null,"abstract":"","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"94 1","pages":"6-11"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75948520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Notoginsenoside R1 is one of major bioactive compounds extracted from Panax notoginseng (Burk.) dry roots and rhizomes of F.H. Chen, which has been increasingly used for enhancing cognition and physical health worldwide. The objective of this study was to review the pharmacological effects of notoginsenoside R1 in a systematic manner. We performed searches on databases including MEDLINE (Pubmed), Google Scholar and Web of Science, the System for Information on to select the original research publications reporting the biological and pharmacological effects of notoginsenoside R1 from in vitro and in vivo studies regardless of publication language and study design. Notoginsenoside R1 exhibited potent characteristics of neuroprotective, anti-inflammatory, anti-apoptosis and anti-ischemia-reperfusion injury properties etc. The cytotoxic effects of notoginsenoside R1 were dependent on different types of cell lines. Other pharmacological effects including accumulation of lipopolysac chaired-induced microcirculation, endothelial injury, hypoxia-reoxygenation injury effects have been mentioned, but the results were considerably diverged. A higher quality of evidence on clinical trial studies is highly recommended to confirm the efficacy of notoginsenoside R1.
Notoginsenoside R1是从三七干根和根茎中提取的主要生物活性化合物之一，在世界范围内越来越多地用于增强认知和身体健康。本文对三七皂苷R1的药理作用进行了系统的综述。我们对MEDLINE (Pubmed)、Google Scholar和Web of Science、the System for Information on等数据库进行了检索，从体外和体内研究中选择了报道三七皂苷R1生物学和药理作用的原始研究出版物，而不考虑出版物的语言和研究设计。三七皂苷R1具有较强的神经保护、抗炎、抗细胞凋亡、抗缺血再灌注损伤等特性。三七皂苷R1对不同类型细胞系的细胞毒作用不同。其他药理作用包括脂溶酶积累、诱导微循环、内皮损伤、缺氧再氧化损伤作用，但结果分歧很大。强烈建议在临床试验研究中有更高质量的证据来证实三七皂苷R1的功效。
{"title":"Notoginsenoside R1: A systematic review of its pharmacological properties.","authors":"Shasha Guo, Xiaozhi Xi, Jia Jia","doi":"10.1691/ph.2019.9534","DOIUrl":"https://doi.org/10.1691/ph.2019.9534","url":null,"abstract":"Notoginsenoside R1 is one of major bioactive compounds extracted from Panax notoginseng (Burk.) dry roots and rhizomes of F.H. Chen, which has been increasingly used for enhancing cognition and physical health worldwide. The objective of this study was to review the pharmacological effects of notoginsenoside R1 in a systematic manner. We performed searches on databases including MEDLINE (Pubmed), Google Scholar and Web of Science, the System for Information on to select the original research publications reporting the biological and pharmacological effects of notoginsenoside R1 from in vitro and in vivo studies regardless of publication language and study design. Notoginsenoside R1 exhibited potent characteristics of neuroprotective, anti-inflammatory, anti-apoptosis and anti-ischemia-reperfusion injury properties etc. The cytotoxic effects of notoginsenoside R1 were dependent on different types of cell lines. Other pharmacological effects including accumulation of lipopolysac chaired-induced microcirculation, endothelial injury, hypoxia-reoxygenation injury effects have been mentioned, but the results were considerably diverged. A higher quality of evidence on clinical trial studies is highly recommended to confirm the efficacy of notoginsenoside R1.","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"492 1","pages":"641-647"},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76702357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of this study was to explore the clinical effect of montelukast sodium chewable tablets combined with inhaled budesonide in the treatment of pediatric asthma and its influence on inflammatory factors. One hundred and thirty-five asthmatic children were randomly divided into montelukast sodium group, budesonide group and combined group. Clinical symptoms, lung function, inflammatory factors and immune related indices of patients in each group were observed and recorded. After treatment, the times to disappearance of wheezes, dyspnea, asthma and hospital stay in the combined group were significantly shorter than those in the single-drug group (all p < 0.001). Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF) were significantly higher than those before treatment, and in the combined group value were significantly higher than in the single-drug group in the same period (all p < 0.001). Tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), IL-8 and hypersensitive C-reactive protein (hs-CRP) were significantly lower than before treatment, and the combined group was significantly lower than the single-drug group in the same period (all p < 0.05). The number of CD4+ and CD3+ cells in the combined group was significantly higher than that in the single-drug group, while the number of CD8 + cells and the expression level of immune globulin E (IgE) were significantly lower (all p < 0.05). There was no difference in the incidence of adverse reactions between the groups during treatment (p > 0.05). Six months after treatment, the incidence of asthma in the combined group was significantly lower than that in the single-drug group (both p < 0.05). Montelukast sodium chewable tablets combined with inhaled budesonide can shorten the discomfort duration of asthmatic children and help them restore lung function. Moreover, it reduces the level of inflammatory factors and increases the resistance of children, which is worthy of further promotion and application.
{"title":"Efficacy of montelukast sodium chewable tablets combined with inhaled budesonide in treating pediatric asthma and its effect on inflammatory factors.","authors":"Yu Zhang, Hai Wang","doi":"10.1691/ph.2019.9582","DOIUrl":"https://doi.org/10.1691/ph.2019.9582","url":null,"abstract":"The aim of this study was to explore the clinical effect of montelukast sodium chewable tablets combined with inhaled budesonide in the treatment of pediatric asthma and its influence on inflammatory factors. One hundred and thirty-five asthmatic children were randomly divided into montelukast sodium group, budesonide group and combined group. Clinical symptoms, lung function, inflammatory factors and immune related indices of patients in each group were observed and recorded. After treatment, the times to disappearance of wheezes, dyspnea, asthma and hospital stay in the combined group were significantly shorter than those in the single-drug group (all p < 0.001). Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF) were significantly higher than those before treatment, and in the combined group value were significantly higher than in the single-drug group in the same period (all p < 0.001). Tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), IL-8 and hypersensitive C-reactive protein (hs-CRP) were significantly lower than before treatment, and the combined group was significantly lower than the single-drug group in the same period (all p < 0.05). The number of CD4+ and CD3+ cells in the combined group was significantly higher than that in the single-drug group, while the number of CD8 + cells and the expression level of immune globulin E (IgE) were significantly lower (all p < 0.05). There was no difference in the incidence of adverse reactions between the groups during treatment (p > 0.05). Six months after treatment, the incidence of asthma in the combined group was significantly lower than that in the single-drug group (both p < 0.05). Montelukast sodium chewable tablets combined with inhaled budesonide can shorten the discomfort duration of asthmatic children and help them restore lung function. Moreover, it reduces the level of inflammatory factors and increases the resistance of children, which is worthy of further promotion and application.","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"22 1","pages":"694-697"},"PeriodicalIF":0.0,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85408116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：